Ivonib (ivitinib)/azacitidine combination shows clinical benefit in IDH1 mutant AML

Based on the results of thePhase 3AGILE trial, for newly diagnosed patientsIDH1mutated acute myeloid leukemia (AML), the combination of ivonib and azacitidine has shown significant therapeutic effects. This regimen has now been approved by the FDA and is especially suitable for patients who are 75 years or older or have other comorbidities that prevent chemotherapy.

Research has found that approximately 6%-10% of AML patients have IDH1 gene mutations. Ivonib, as a highly effective oral targeted inhibitor, provides new treatment opportunities for these patients. AGILEPreliminary results of the study show that compared with only using azacitidine plus placebo, after adding ivonib, the median survival time of patients was significantly improved to 24 months, and the event-free survival rate and complete remission rate were also significantly improved.

In the combination treatment group of ivonib and azacitidine, the percentage of bone marrow blasts decreased rapidly and remained at a low level for a longer period of time. At the same time, compared with the placebo group, this group also showed advantages in terms of safety, such as a lower incidence of adverse events such as febrile neutropenia.

Although some anemia and thrombocytopenia occurred in the combination group, they were not significantly increased compared with the placebo group. In terms of non-hematological adverse events, such as nausea, vomiting, diarrhea, fever, etc., there was no significant difference between the combination group and the placebo group.

Overall, the combination treatment regimen of ivonib and azacitidine has shown encouraging results in terms of survival, response rate, and safety for patients with newly diagnosed IDH1mutantAML. This solution undoubtedly brings new treatment hope to these patients.